High-Dimensional DNA Methylation Mediates the Effect of Smoking on Crohn’s Disease

Tingting Wang1*, Pingtian Xia2† and Ping Su1

1Institute of Medical Sciences, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China, 2Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

Epigenome-wide mediation analysis aims to identify high-dimensional DNA methylation at cytosine–phosphate–guanine (CpG) sites that mediate the causal effect of linking smoking with Crohn’s disease (CD) outcome. Studies have shown that smoking has significant detrimental effects on the course of CD. So we assessed whether DNA methylation mediates the association between smoking and CD. Among 103 CD cases and 174 controls, we estimated whether the effects of smoking on CD are mediated through DNA methylation CpG sites, which we referred to as causal mediation effect. Based on the causal diagram, we first implemented sure independence screening (SIS) to reduce the pool of potential mediator CpGs from a very large to a moderate number; then, we implemented variable selection with de-sparsifying the LASSO regression. Finally, we carried out a comprehensive mediation analysis and conducted sensitivity analysis, which was adjusted for potential confounders of age, sex, and blood cell type proportions to estimate the mediation effects. Smoking was significantly associated with CD under odds ratio (OR) of 2.319 (95% CI: 1.603, 3.485, \( p < 0.001 \)) after adjustment for confounders. Ninety-nine mediator CpGs were selected from SIS, and then, seven candidate CpGs were obtained by de-sparsifying the LASSO regression. Four of these CpGs showed statistical significance, and the average causal mediation effects (ACME) were attenuated from 0.066 to 0.126. Notably, three significant mediator CpGs had absolute sensitivity parameters of 0.40, indicating that these mediation effects were robust even when the assumptions were slightly violated. Genes (BCL3 and FKBP5) harboring these four CpGs were related to CD. These findings suggest that changes in methylation are involved in the mechanism by which smoking increases risk of CD.

Keywords: epigenome wide, DNA methylation, mediation effect, causal diagram, smoking

INTRODUCTION

Inflammatory bowel disease (IBD) is a complex etiology comprising Crohn’s disease (CD) and ulcerative colitis (UC) (Severs et al., 2016). Previous studies have shown that the relationship between smoking and IBD is complex and remains the most independent and prominent risk factor. It is well established that smoking has significant detrimental effects on the course of CD, but it has a beneficial influence on the development of UC (Tanja Birrenbach MUBM, 2004; Khasawneh et al., 2017; Nicolaides et al., 2021; van der Sloot et al., 2021). However, the efficacy of smoking on IBD
remains largely unknown. Furthermore, it is less clear how smoking impacts the biological mechanism of CD.

DNA methylation has a role in the immune dysfunction phenotype associated with IBD, as it is influenced by certain smoking (Tsaprouni et al., 2014) known to be associated with inflammatory diseases (McDermott et al., 2015). DNA methylation is a crucial mechanism associated with environmental exposures, particularly smoking and alcohol (Lee and Pausova, 2013; Tsaprouni et al., 2014; Joehanes et al., 2016; Jenkins et al., 2017; Sharp et al., 2018; Zhang et al., 2018), and complex diseases such as rheumatoid arthritis, type 2 diabetes, and IBD (Liu et al., 2013; Ventham et al., 2016; Davegårdh et al., 2018). In epigenetic studies, it is of increasing scientific interest to study the mediating role of DNA methylation in the etiology of human diseases (Liu et al., 2013; Ventham et al., 2016; Zhang et al., 2016; Kular et al., 2018). Epigenome-wide association studies (EWASs) have explored associations of DNA methylation across the genome and identified epigenetic marks of disease (Dick et al., 2014; Wahl et al., 2017). Previous studies have focused on associations between DNA methylation and either exposure/outcomes, it is useful to test for mediation of the effect of exposure on outcome by DNA methylation (Fujii et al., 2021). Based on the causal inference, DNA methylation may act as potential mediator linking environmental exposure and disease outcomes. Recently, increasing evidence points towards a major role for epigenetic mechanisms of DNA methylation in regulating the fundamental behavior of CD. Studies have detected the links between 25 CpG sites and CD as well as the links between 13 CpG sites and UC with specific DNA methylation (Lin et al., 2011; Karatzas et al., 2014). However, limited data exist concerning the contribution of DNA methylation to CD pathogenesis. Epigenome-wide mediation analysis needs to be conducted in ultra-high-dimensional DNA methylation CpG sites simultaneously to explore statistically significant CpG sites. Karatzasa et al. showed the different known genes whose methylation has been related to IBD, CD, or UC, respectively (Karatzas et al., 2014). Recent work has been focused on researching associations between genetic risk and IBD through DNA methylation (Ventham et al., 2016). However, few studies have examined the role of smoking associated with DNA methylation on the development mechanism of CD.

DNA methylation is immensely cell-type specific, and several studies have demonstrated the impacts of cellular heterogeneity on the DNA methylation status (Liu et al., 2013; Jaffe and Irizarry, 2014; Inoshita et al., 2015; Shu et al., 2020), which may act as a potential confounder when investigating the effect of DNA methylation on disease. Therefore, we adjusted for confounders of age, sex, and blood cell type proportions to estimate the mediation effects. Currently, there is a focus on high-dimensional mediation analysis in epigenome-wide mediation. Based on the concept of SIS and regularization techniques (minimax concave penalty, MCP) in a high-dimensional mediation analysis, Zhang et al. (Zhang et al., 2016) established a HIMA model to identify DNA methylations mediating the relationship between smoking and lung function. In summary, CpG sites with DNA methylation that mediate the effect of smoking on CD to improve techniques for early disease detection and prevention are identified.

In this study, we identify the mediating effect of the association between smoking and CD through methylation mechanisms at CpG sites. We applied the multiple-mediator causal model framework to estimate and test unbiased mediation effects in high-dimensional epigenetic studies, in particular the existence of omitted variables or confounders. In the primary analysis, we first reduced the pool of potential mediator CpGs using the SIS (Fan and Lv, 2008) method and further conducted variable selection with the de-sparsified LASSO (Dezeure et al., 2014; van de Geer et al., 2014). By de-sparsifying the LASSO coefficients, one can reduce the estimation bias and obtain the asymptotic normality of the regression estimates. Finally, we implemented mediation analysis to assess the mediation effect of smoking on CD. We further estimated causal mediation effects and conducted sensitivity analysis for the possible existence of confounding by unmeasured covariates. Our results provide new insights into the role of DNA methylation in how smoking affects CD.

**METHODS**

**Subjects**

Datasets were obtained from a case–control study of DNA methylation and IBD. The genome-wide DNA methylation data using the Illumina 450K methylation array are available at the Gene Expression Omnibus (GEO) website under accession GSE87648 to identify IBD-associated epigenetic analysis (Ventham et al., 2016). In our study, exposure was a binary variable, smoking (current versus former smokers or never smokers). After subjects with missing smoking status were excluded, the final dataset comprised 103 CD cases and 174 controls (symptomatic and healthy controls) with DNA methylation data available being used for mediation analyses (Ventham et al., 2016).

**Methylation Data**

First of all, we carried out a series of quality control: probes with detection p-value (default ≥0.01) and samples with a mean p-value of all probes greater than 0.05 were filtered out; a total of 28,931 probes containing SNPs (MAF ≥ 0.05) in their sequences were also removed from the final data; and all probes located in chromosomes X and Y were filtered out. Meanwhile, for normalization of methylation data, a quantile normalization algorithm (Fortin et al., 2014) was the normalization method of the Illumina Infinium HumanMethylation450 platform to remove unwanted variation by regressing out variability explained by the control probes present on the array (Amiri Roudbar et al., 2020). The above-described methylation markers were standardized to ensure that the coefficients are in the same scale. After data preprocessing, 242,594 methylation sites were available for the downstream analysis. All methylation array data preprocessing was conducted with the R package minfi (Aryee et al., 2014). A study indicated that the M-value was more statistically accepted than the beta value for the differential methylation analysis (Du
et al., 2010). Thus, the DNA methylation level was calculated as the M-value for our statistical analysis.

**Statistical Analysis**

The causal graph model in Figure 1 assumed independence of multiple causal mechanisms in situations with confounders. X and Y represent exposure (smoking) and outcome (CD), respectively. \( M = (M_1, \ldots, M_p) \) denotes high-dimensional mediators \((\text{CpG sites})\) that we are interested in for their effects independent of the pathway from exposure to outcome. Suppose that there are multiple causally unrelated mediators and that one is interested in estimating the causal mediation effects with respect to each of them. Let \( C \) denote some set of comprehensive confounders \((\text{sex, age, estimated CD8' T cells, CD4' T cells, natural killer (NK) cells, B cells, monocytes, and granulocytes)}\) that may affect the mediator and outcome.

**Association Between Smoking and CD at Baseline**

This analysis was conducted using baseline information on smoking, CD, and confounders (Figure 1). The following logistic regression model was used to test the association of smoking and CD, adjusting for confounders:

\[
\logit(P) = \beta_0 + \beta_1 \text{smoking} + \beta_2 \text{age} + \beta_3 \text{sex} + \beta_4 \text{CD8T} + \beta_5 \text{CD4T} + \\
\beta_6 \text{NKcell} + \beta_7 \text{Bcell} + \beta_8 \text{monocytes} + \beta_9 \text{granulocytes}
\]

**Mediator Screening and Mediation Effect Analysis**

First, for the purpose of dimension reduction analysis, a high dimension may lead to false associations between covariates and response variables. We implemented SIS \((\text{Fan and Lv, 2008)}\) to reduce the dimensionality of high-dimensional mediator CpG sites. Let \( M_s = \{1 \leq i \leq p: \beta_i \neq 0\} \) be the true sparse model with non-sparsity size \( s = |M_s| \). And then let \( \omega = (\omega_1, \ldots, \omega_p)^T \), for any given \( y \in (0, 1) \); we sort the \( p \) componentwise magnitudes of the vector \( \omega \) in decreasing order and define a submodel \( M_T = \{1 \leq i \leq p: |\omega| \text{ is among the first } [\gamma n] \text{ largest of all} \} \), where \([\gamma n]\) denotes the integer part of \( \gamma n \) and \([\gamma n] < n \). The SIS method was used for a rough dimension reduction to reduce the ultra-high-dimensional model to \( d = n \) dimension depending on the order of sample size \( n \) \((n = 277)\). It was crucial that the SIS of a fast and efficient method reduce dimensionality from a large or huge scale to a relatively large scale. Therefore, to identify important mediators with the largest effects for the response, SIS identifies mediators of the top \( d = 2n \log(n) \) \((\text{Zhang et al., 2016)}\) instead of \( d = n/\log(n) \) \((\text{Fan and Lv, 2008)}\).

Second, after dimensionality reduction of SIS, variable selection was carried out next. On account of the LASSO estimates being biased and without the testing to asymptotic normality property, previous studies proposed the asymptotic normality for the de-sparsified estimates for high-dimensional data \((\text{Dezeure et al., 2014; van de Geer et al., 2014)}\). Dezeure et al. \((2014)\) did a comprehensive method for high-dimensional inference to test the regression coefficient. The method was based on the asymptotic normality of de-sparsifying the LASSO regression to obtain the bias-corrected regression coefficient following van de Geer et al. \((2014)\), and furthermore, we could get a \( p \)-value for each mediator. De-sparsifying the LASSO procedure has been implemented in R package hdi \((\text{Dezeure et al., 2014)}\). In the paper, we described the de-sparsifying approach for a binary outcome CD. Let \( \rho_\beta(y, x) = \rho(y, x \beta) \) be a loss function, and define \( \hat{\beta}^\rho = \frac{1}{n} \hat{\rho}^\beta \) and \( \hat{\beta} = \frac{1}{n} \hat{\rho} \), and further define \( P_{\rho \beta} = \sum_{i=1}^{n} g(y_i, x_i)/n \). The LASSO estimator for the CpG coefficients \( \beta \) was given as \( \hat{\beta} = \arg \min \{ P_{n \rho \beta} + \lambda \| \beta \|_1 \} \), where \( \lambda \) was a tuning parameter. Define \( \Sigma \hat{\beta} = P_{n \rho \beta} \) and construct \( \hat{\Theta} = \hat{\Theta}_{\text{LASSO}} \) by doing a nodewise LASSO with \( \Sigma \) as input. Then the de-sparsified LASSO estimator was given as \( \hat{\beta} = \hat{\Theta}^{-1} \hat{\Theta}_{\text{LASSO}} \hat{\beta} \), van de Geer et al. \((2014)\) gave the detailed algorithm for computing the de-sparsified LASSO estimators in a generalized linear model framework. It was crucial that the method under the generalized linear model could reduce the estimation bias and obtain the asymptotic normality of the regression estimates \((\text{van de Geer et al., 2014)}\). Furthermore, we could obtain a \( p \)-value for each CpG site based on the asymptotic normality of the de-sparsified LASSO estimates. Studies of van de Geer et al. \((2014)\), Dezeure et al. \((2014)\), and Wu et al. \((2018)\) provided detailed information about the de-sparsified LASSO estimates. Meanwhile, we corrected the multiple testing by using a false discovery rate \((\text{FDR})\) of 5\% \((<0.05)\).

Finally, with the reduced dimension, the below-described procedures can be followed to assess the mediation effect. Among the selected mediators, we estimate the average direct effects \((\text{ADE})\) and the average causal mediation effects \((\text{ACME})\) of the mediator based on the mediation package in R \((\text{Tingley et al., 2014)}\). To assess the robustness of the results if the sequential ignorability \((\text{SI})\) assumption was violated, we conducted a sensitivity analysis developed by Imai et al. \((2010a)\). Our article assumes the following as regards SI: (1) it is conditional on the covariates, and the exposure is independent of all potential values of the outcome and mediator; and (2) the observed mediator is independent of all potential outcomes given the observed exposure and covariates \((\text{Imai et al., 2010b; Imai and Yamamoto, 2013; Shu et al., 2020)}\). The sensitivity parameter is the correlation \( \rho \) between the residuals of the mediator and outcome regression \((\text{Imai et al., 2010a)}\).

![The causal diagram with high-dimensional mediators.](image-url)
sensitivity plots were illustrated to show the estimated ACME and their 95% confidence interval as a function of \( \rho \). If the \( \rho \) at which ACME = 0 was close to 0, it indicates that the mediation analysis was sensitive to violation of the SI assumption.

In mediation analysis, for each candidate CpG mediator, we fitted the following statistical models: (1) the mediator model, the CpG site \((M)\) as the outcome and smoking \((X)\) as a predictor, adjusting for the confounders sex, age, and estimated cell-type proportions; and (2) the outcome model, with CD8 \((Y)\) as the outcome and smoking \((X)\) as a predictor, adjusting for the mediator, i.e., the CpG site \((M)\), and the covariates from the first model.

The Mediator Model Was Fit

\[
E[M|x,c] = \beta_0 + \beta_1 x + \beta_2 \text{age} + \beta_3 \text{sex} + \beta_4 CD8^+ T + \beta_5 CD4^+ T + \beta_6 NKcells + \beta_7 Bcells + \beta_8 monocytes + \beta_9 granulocytes
\]

\[
\log\{P(Y = 1|x,m,c)\} = \theta_0 + \theta_1 x + \theta_2 m + \theta_3 \text{age} + \theta_4 \text{sex} + \theta_5 CD8^+ T + \theta_6 CD4^+ T + \theta_7 NKcells + \theta_8 Bcells + \theta_9 monocytes + \theta_{10} \text{granulocytes}
\]

Then the ADE and ACME odds ratios are given by VanderWeele and Vansteelandt (2014):

\[
\log(OR)_{\text{ADE}} = \theta_1
\]

\[
\log(OR)_{\text{ACME}} = \beta_1 \beta_2
\]

The estimates and 95% confidence intervals were estimated by nonparametric bootstrapping with 1,000,000 iterations (Tingley et al., 2014).

## RESULTS

The distribution of demographic and clinical characteristics based on baseline case–control status is summarized in Table 1. A total of six different cell types including two types of T cells (CD8+ T cells and CD4+ T cells), NK cells, B cells, monocytes, and granulocytes. Table 1 shows that the cell-type proportions (CD8+ T cells, CD4+ T cells, NK cell, B cell, monocyte, and granulocyte) for each of the samples were estimated using the estimateCellCounts function implemented in a flexible and comprehensive bioconductor “Minfi” (Aryee et al., 2014), which obtained sample-specific estimates of cell proportions based on reference information on cell-specific methylation signatures (Houseman et al., 2012).

The mean age of cases was 38.738 (standard deviation (SD), 16.266) years, which is older than that of the controls by 3 years. There was no significant statistical difference between the age and sex. On average, controls had a higher proportion of CD8+ T cells, CD4+ T cells, NK cells, and B cells. Compared to controls, a larger proportion of cases were granulocytes cells. Notably, there was a significant difference in smoking.

## Association Between Smoking and CD at Baseline

We found that the effect of smoking on the CD using the logistic regression model remained significant with an odds ratio \( OR \) of 2.319 (95% CI: 1.603, 3.485, \( p < 0.001 \)), adjusting for sex, age, CD8+ T cells, CD4+ T cells, NK cells, B cells, monocytes, and granulocytes (Table 2). The results suggested that smoking accelerated CD progression, which was consistent with previous reports (Nicolaides et al., 2021; van der Sloot et al., 2021).

## Dimensionality Reduction and Mediation Analysis

A total of \( d = 2n/\log(n) = 99 \) CpGs met our candidate selection through the SIS method. As shown in Table 3, the results of de-sparsifying the LASSO showed seven CpGs by multiple testing correction, i.e., an \( FDR \) of \( P_{FDR} < 0.05 \) in models adjusted for sex, age, CD8+ T cells, CD4+ T cells, NK cells, B cells, monocytes, and granulocytes. The effect size of CpGs was positive (cg04287259 and cg05941027) or negative (cg25114611, cg10180440, cg19821297, cg26470501, and cg09349128), but the absolute effect value was greater than 2. The standard error (SE, i.e., prediction accuracy) from de-

### Table 1 | Sample characteristics and differential cell-type proportions.

| Variables     | Controls (n = 174) | Cases (n = 103) | z   | p-value |
|---------------|--------------------|-----------------|-----|---------|
| Age           | 35.667 (±12.459)   | 38.738 (±16.266)| −1.651 | 0.101   |
| Smoking (N, %)|                    |                 |     |         |
| Current       | 38 (0.218)         | 48 (0.466)      |     |         |
| Sex (N, %)    | 136 (0.782)        | 55 (0.534)      |     |         |
| Male          | 87 (0.5)           | 53 (0.515)      |     |         |
| Female        | 87 (0.5)           | 50 (0.485)      |     |         |
| CD8+ T cells  | 0.104 (±0.046)     | 0.067 (±0.043)  | 6.521 | <0.001  |
| CD4+ T cells  | 0.147 (±0.062)     | 0.101 (±0.069)  | 5.675 | <0.001  |
| NK cells      | 0.04 (±0.038)      | 0.024 (±0.037)  | 3.346 | 0.001   |
| B cells       | 0.081 (±0.033)     | 0.06 (±0.026)   | 5.684 | <0.001  |
| Monocytes     | 0.065 (±0.022)     | 0.067 (±0.028)  | −0.693| 0.489   |
| Granulocytes  | 0.599 (±0.11)      | 0.71 (±0.124)   | −7.755| <0.001  |

### Table 2 | The estimation of smoking by logistic regression.

| Variable | Estimation | SE | OR (95% CI) | p      |
|----------|------------|----|-------------|--------|
| Smoking  | 0.841      | 0.191 | 2.319 (1.603, 3.485) | <0.001 |

### Table 3 | The correction \( p \)-value of de-sparsifying the LASSO method.

| CpG       | \( p \) | FDR* | Estimation | 95% CI     | SE     |
|-----------|--------|------|------------|------------|--------|
| cg04287259| 0.001  | 0.031 | 3.123      | (1.202, 5.051) | 0.982  |
| cg25114611| 0.001  | 0.031 | −3.279     | (−5.227, −1.332) | 0.994  |
| cg10180440| 0.003  | 0.042 | −2.040     | (−3.372, −0.707) | 0.680  |
| cg05941027| 0.003  | 0.042 | 2.478      | (0.870, 4.086)  | 0.820  |
| cg19821297| 0.001  | 0.031 | −2.169     | (−3.499, −0.839) | 0.679  |
| cg26470501| <0.001 | 0.031 | −4.846     | (−6.941, −2.030) | 1.253  |
| cg09349128| 0.001  | 0.031 | −2.441     | (−3.932, −0.951) | 0.761  |

*SE, standard error.

*FDR-adjusted \( p \)-value.

Frontiers in Genetics | www.frontiersin.org 4 April 2022 | Volume 13 | Article 831885
sparsifying the LASSO method was relatively small, varying from 0.6791 to 1.253.

Then, we also analyzed the relationship between smoking and the above CpGs (cg04287259, cg25114611, cg10180440, cg05941027, cg19821297, cg26470501, and cg09349128), focusing on positive and negative effect sizes. As shown in Table 4, the effect of smoking was positive (cg04287259 and cg05941027), and the effect size of CpGs was negative (cg25114611, cg10180440, cg19821297, cg26470501, and cg09349128). Notably, the statistical test of the CpGs (cg25114611, cg19821297, cg26470501, and cg09349128) was significant. Notably, these four CpGs were hypomethylated in the smoking group compared to the non-smoking group (Figure 2).

For mediation analyses, we identified four potential CpGs (cg25114611, cg19821297, cg26470501, and cg09349128) from the above seven candidate CpGs in the mediation models, adjusting for sex, age, CD8+ T cells, CD4+ T cells, NK cells, B cells, monocytes, and granulocytes under statistical significance mediation effects (ACME, p-value < 0.05), which were shown in Table 5. Four CpGs showed significant ACME, with p-values ranging from 0.001 to 0.012 (Table 5). In Table 5, notably, the directions of ACME and ADE among these four mediator CpGs were positive. The ADE of smoking on CD was attenuated from 0.129 to 0.211 after adjusting for each mediator CpG and covariates. In a comparison with the unadjusted mediator log (OR) of 0.841 in Table 2, it is shown that adjusting for the mediator underestimated the total effect of exposure smoking on outcome CD, which was consistent with previous reports (Wang et al., 2017). The DNA methylation of cg25114611 annotated to the FKBP prolyl isomerase 5 (FKBP5) gene TSS1500, with an average mediated effect of 0.082 (95% CI: 0.030, 0.141). The cg19821297 had a mediated effect of 0.066 (95% CI: 0.014, 0.125). The cg26470501 annotated to the BCL3 transcription coactivator (BCL3) gene body, with a mediated effect of 0.118 (95% CI: 0.062, 0.181). The cg09349128 obtained a mediated effect of 0.126 (95% CI: 0.071, 0.182).

**Table 4**: The estimation effect of smoking.

| CpG         | Estimation | SE  | t-value | p       |
|-------------|------------|-----|---------|---------|
| cg04287259  | 0.048      | 0.026 | 1.867   | 0.063   |
| cg25114611  | -0.106     | 0.031 | -3.409  | 0.001   |
| cg10180440  | -0.05      | 0.032 | -1.543  | 0.124   |
| cg05941027  | 0.034      | 0.022 | 1.508   | 0.133   |
| cg19821297  | -0.109     | 0.030 | -3.711  | 0.001   |
| cg26470501  | -0.131     | 0.025 | -5.24   | <0.001  |
| cg09349128  | -0.166     | 0.036 | -4.599  | <0.001  |

SE, standard error

**Figure 2**: DNA methylation level of the significant CpG mediators by smoking status.
In epigenetic studies, it is crucial that DNA methylation marks are often considered potential mediators between exposures and outcomes. Numerous studies have established a clear relationship between DNA methylation and various diseases, including inflammatory bowel disease (IBD). Hypomethylation of certain CpG sites has been associated with the expression of genes involved in cell growth and energy metabolism (Beharry et al., 2011) and glucose-stimulated insulin secretion in β cells (Vlacich et al., 2010). In addition, cg19821297 showed evidence of mutational analyses could help to identify subgroups of CD with higher chances of benefiting from glucocorticoid treatment (Maltese et al., 2012). FKBP5 revealed a significant impact on the glucocorticoid treatment response, which could result in valuable pharmacogenetic biomarkers after being confirmed in other populations and in functional studies (Skrzypczak-Zielinska et al., 2021). In addition, Tobi et al. (2018) illustrated that DNA methylation acted as a mediator of the association between prenatal adversity and risk factors for metabolic disease, and it has been shown that methylation of cg09349128 was associated with the expression of PIM3, a gene implicated in cell growth and energy metabolism (Beharry et al., 2011) and glucose-stimulated insulin secretion in β cells (Vlacich et al., 2010). In addition, the cg19821297 showed evidence of genetic influences on DNA methylation being associated with the inflammation-related epigenetic polygene (Barker et al., 2018). Furthermore, the findings that CpGs were hypomethylated provided insight into the complex interaction of genetics and epigenetics in the pathophysiology of IBD (Kalla, 2021). Besides, it has been shown that the key question was whether the hypomethylation CpG site was involved in the causal pathway (Fasanelli et al., 2015). We speculated that hypomethylation may have a crucial role in regulated inflammation.

An important strength of our causal diagram is the implementation of the counterfactual framework in mediation analysis to estimate the effects in the presence of confounders as a relevant biological model for epigenetic epidemiology. We applied screening criteria (SIS) and dimension reduction (de-sparsifying the LASSO) to select CpGs with the top largest effects.

### DISCUSSION

Smoking is an established risk factor for the development of CD. Our results suggest that smoking might play an important role in the well-established association of smoking and CD through DNA methylation variability. Our results also highlight the need to consider various confounding factors in epigenetic studies as a relevant biological and statistical model.

In epigenetic studies, it is crucial that DNA methylation plays a mediator role in the etiology of human diseases (Liu et al., 2013; Venthom et al., 2016; Zhang et al., 2016; Kular et al., 2018). Methylation marks are often considered potential mediators between exposures and outcomes. Numerous studies have established a clear relationship between smoking and the occurrence of IBD and its significantly detrimental effects on CD, whereas the opposite is the beneficial influence of the development of UC (Tanja Birrenbach MUBM, 2004; Khasawneh et al., 2017; Nicolaides et al., 2021; van der Sloot et al., 2021). What is less clear is whether smoking impacts the biological mechanism in CD by mediating DNA methylation.

In this article, we adopted three steps to estimate the mediation effects with high-dimensional mediator DNA methylation. We used the SIS and de-sparsified the LASSO method to reduce the dimension of potential mediators and the mediation significance test for mediation effects. Furthermore, our findings provided evidence that smoking affects CD through high-dimensional DNA methylation mediators. The results from the sensitivity test showed that the four mediator CpGs were robust when slight violation of the SI assumption was present. In our paper, we found that the differential methylation positions, such as cg26470501 (BCL3), were affected between IBD cases and controls. And the study found drastically elevated expression levels of BCL3 in CD4+ T cells isolated from patients with CD and UC, underlining a role for BCL3 in the pathogenesis of IBD (Reifig et al., 2017). Another study showed that the combination of glucocorticoid receptor (GR) and FKBP5 (the cg25114611 annotated to the FKBP5 gene) mutational analyses could help to identify subgroups of CD with higher chances of benefiting from glucocorticoid treatment (Maltese et al., 2012). FKBP5 revealed a significant impact on the glucocorticoid treatment response, which could result in valuable pharmacogenetic biomarkers after being confirmed in other populations and in functional studies (Skrzypczak-Zielinska et al., 2021). In addition, Tobi et al. (2018) illustrated that DNA methylation acted as a mediator of the association between prenatal adversity and risk factors for metabolic disease, and it has been shown that methylation of cg09349128 was associated with the expression of PIM3, a gene implicated in cell growth and energy metabolism (Beharry et al., 2011) and glucose-stimulated insulin secretion in β cells (Vlacich et al., 2010). In addition, the cg19821297 showed evidence of genetic influences on DNA methylation being associated with the inflammation-related epigenetic polygene (Barker et al., 2018).

### TABLE 5 | Mediation analysis on candidate CpGs between smoking and CD.

| CpG     | Chr | Position | Nearest gene | References gene group | ACME Effect estimate | 95% CI         | p-value | ADE Effect estimate | 95% CI         | p-value | Sensitivity analysis rho when ACME = 0 |
|---------|-----|----------|--------------|-----------------------|---------------------|---------------------|---------|---------------------|---------------------|---------|---------------------------------------|
| cg25114611 | chr6 | 35,696,870 | FKBP5 | TSS1500 | 0.082 | (0.030, 0.141) | 0.001 | 0.19 | (0.080, 0.293) | 0.001 | -0.4 |
| cg19821297 | chr19 | 12,890,029 | — | — | 0.066 | (0.014, 0.125) | 0.012 | 0.211 | (0.009, 0.315) | <0.001 | -0.4 |
| cg26470501 | chr19 | 45,252,955 | BCL3 | Body | 0.118 | (0.062, 0.181) | <0.001 | 0.145 | (0.030, 0.255) | 0.012 | -0.4 |
| cg09349128 | chr22 | 50,327,986 | — | — | 0.126 | (0.070, 0.196) | <0.001 | 0.129 | (0.036, 0.238) | 0.008 | -0.5 |

FKBP5, FKBP prolyl isomerase 5; BCL3, BCL3 transcription coactivator; CI, confidence interval.

CI: 0.070, 0.196). The average mediation effects of smoking on CD were attenuated from 0.066 to 0.126.

In sensitivity analyses of the mediated effect estimates, the SI assumption might be violated for residual correlations of the mediator and outcome regressions far from the observed estimated mediated effects on the above four CpGs. And then, we also conducted a sensitivity analysis on the above four CpGs to assess the robustness of our mediation analysis when the SI assumption was violated. Notably, the absolute sensitivity parameters at which ACME = 0 in the four mediator CpGs were 0.4 or 0.5, indicating that these mediation effects were robust even when the assumptions were slightly violated (Supplementary Figure S1 and Supplementary Table S1). The sensitivity analysis showed that our mediation results were relatively stable.

References

Fasanelli et al., 2015; Vanden Sloote et al., 2021. What is less clear is whether smoking impacts the biological mechanism in CD by mediating DNA methylation.

In this article, we adopted three steps to estimate the mediation effects with high-dimensional mediator DNA methylation. We used the SIS and de-sparsified the LASSO method to reduce the dimension of potential mediators and the mediation significance test for mediation effects. Furthermore, our findings provided evidence that smoking affects CD through high-dimensional DNA methylation mediators. The results from the sensitivity test showed that the four mediator CpGs were robust when slight violation of the SI assumption was present. In our paper, we found that the differential methylation positions, such as cg26470501 (BCL3), were affected between IBD cases and controls. And the study found drastically elevated expression levels of BCL3 in CD4+ T cells isolated from patients with CD and UC, underlining a role for BCL3 in the pathogenesis of IBD (Reifig et al., 2017). Another study showed that the combination of glucocorticoid receptor (GR) and FKBP5 (the cg25114611 annotated to the FKBP5 gene) mutational analyses could help to identify subgroups of CD with higher chances of benefiting from glucocorticoid treatment (Maltese et al., 2012). FKBP5 revealed a significant impact on the glucocorticoid treatment response, which could result in valuable pharmacogenetic biomarkers after being confirmed in other populations and in functional studies (Skrzypczak-Zielinska et al., 2021). In addition, Tobi et al. (2018) illustrated that DNA methylation acted as a mediator of the association between prenatal adversity and risk factors for metabolic disease, and it has been shown that methylation of cg09349128 was associated with the expression of PIM3, a gene implicated in cell growth and energy metabolism (Beharry et al., 2011) and glucose-stimulated insulin secretion in β cells (Vlacich et al., 2010). In addition, the cg19821297 showed evidence of genetic influences on DNA methylation being associated with the inflammation-related epigenetic polygene (Barker et al., 2018). Furthermore, the findings that CpGs were hypomethylated provided insight into the complex interaction of genetics and epigenetics in the pathophysiology of IBD (Kalla, 2021). Besides, it has been shown that the key question was whether the hypomethylation CpG site was involved in the causal pathway (Fasanelli et al., 2015). We speculated that hypomethylation may have a crucial role in regulated inflammation.

An important strength of our causal diagram is the implementation of the counterfactual framework in mediation analysis to estimate the effects in the presence of confounders as a relevant biological model for epigenetic epidemiology. We applied screening criteria (SIS) and dimension reduction (de-sparsifying the LASSO) to select CpGs with the top largest effects.
and the bias-corrected regression coefficient for the outcome. Then, we conducted mediation analyses of smoking (exposure) on CD (outcome) through DNA methylation (mediator).

One limitation of the study is that our sample size for the mediation analyses is small. Using epigenome-wide significant CpG sites as candidate mediators may show stronger signals in a future study with a larger sample size. In particular, the presence of unmeasured confounders may make it impossible to distinguish causal from consequential methylation events based on observational data alone (Kang et al., 2010). Therefore, in a further study, to validate unmeasured confounding factors, we will adopt the two-step epigenetic Mendelian randomization method to estimate the mediation effect (Relton and Davey Smith, 2012).

In conclusion, this study was based on epigenetic DNA methylation data and elucidated the mechanisms related to environmental factors involved in susceptibility to IBD. Furthermore, it makes more biological sense to identify the high-dimensional mediation effect of the whole gene rather than focus on individual methylation sites when performing a mediation analysis in an epigenetic study. Nevertheless, a statistical mediation approach might not accurately reflect the underlying causal biological mechanism. The study found that several biologically meaningful DNA methylation sites mediated the effect of smoking on CD. In future studies, the highly plausible biological mechanisms on how smoking influences CD outcome are revealed by these DNA methylation sites.

REFERENCES

Amiri Roudbar, M., Mohammadadabi, M. R., Ayatollahi Mehrgardi, A., Abdollahi-Arpanahi, R., Momen, M., Morota, G., et al. (2020). Integration of Single Nucleotide Variants and Whole-Genome DNA Methylation Profiles for Classification of Rheumatoid Arthritis Cases from Controls. *Heredity* 124, 658–674. doi:10.1038/s41437-020-0301-4

Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., et al. (2014). Minfi: a Flexible and Comprehensive Bioconductor Package for the Analysis of Infinium DNA Methylation Microarrays. *Bioinformatics* 30, 1363–1369. doi:10.1093/bioinformatics/btu049

Barker, E. D., Cecil, C. A. M., Walton, E., Houtepen, L. C., O’Connor, T. G., Danese, A., et al. (2018). Inflammation-related Epigenetic Risk and Child and Adolescent Mental Health: A Prospective Study from Pregnancy to Middle Adolescence. *Development Psychopathology* 30, 1145–1156. doi:10.1017/S0954579418000330

Beharry, Z., Mahajan, S., Zemskova, M., Lin, Y. W., Tholanikunnel, B. G., Xia, Z., et al. (2011). The Pim Protein Kinases Regulate Energy Metabolism and Cell Growth. *Proc. Natl. Acad. Sci. USA* 108, 528–533. doi:10.1073/pnas.1013214108

Davegårdh, C., Garcia-Calzón, S., Bacos, K., and Ling, C. (2018). DNA Methylation in the Pathogenesis of Type 2 Diabetes in Humans. *Mol. Metab.* 14, 12–25. doi:10.1016/j.molmet.2018.01.022

Dezure, R., Bühlmann, P., Meier, L., and Meinshausen, N. (2014). High-dimensional Inference Confidence Intervals, P-Values and R-Software Hdi. *Stat. Sin.* 30, 533–558. doi:10.1214/15-STS552

Dick, K. J., Nelson, C. P., Tsaprouni, L., Sandling, J. K., Assi, D., Wahl, S., et al. (2014). DNA Methylation and Body-Mass index: a Genome-wide Analysis. *The Lancet* 383, 1990–1998. doi:10.1016/S0140-6736(13)62674-4

Du, P., Zhang, X., Huang, C. C., Jafari, N., Kibbe, W. A., and Hou, L. (2010). Comparison of Beta-Value and M-Value Methods for Quantifying Methylation Levels by Microarray Analysis. *BMC Bioinformatics* 11, 587. doi:10.1186/1471-2105-11-587

Fan, J., and Lv, J. (2008). Sure independence Screening for Ultrahigh Dimensional Feature Space. *J. R. Statist. Soc. B* 70, 849–911. doi:10.1111/j.1467-9868.2008.00674.x

Fasanelli, F., Baglietto, L., Ponzi, E., Guida, F., Campanella, G., Johansson, M., et al. (2015). Hypomethylation of Smoking-Related Genes Is Associated with Future Lung Cancer in Four Prospective Cohorts. *Nat. Commun.* 6, 10192. doi:10.1038/ncomms10192

Fortin, J., Labbe, A., Lemire, M., Zanke, B. W., Hudson, T. J., Fertig, E. J., et al. (2014). Functional Normalization of 450k Methylation Array Data Improves Replication in Large Cancer Studies. *Genome Biol.* 15, 503. doi:10.1186/s13059-014-0503-2

Fujii, R., Sato, S., Tsuboi, Y., Cardenas, A., and Suzuki, K. (2021). DNA Methylation as a Mediator of Associations between the Environment and Chronic Diseases: A Scoping Review on Application of Mediation Analysis. *Epidemiol. Genomics* 1, 1–27. doi:10.1080/15592924.2021.1959736

Houseman, E. A., Accomando, W. P., Koestler, D. C., Christensen, B. C., Marsit, C. J., and Nelson, H. H. (2012). DNA Methylation Arrays as Surrogate Measures of Cell Mixture Distribution. *BMC Bioinformatics* 13, 86. doi:10.1186/1471-2105-13-86

Imai, K., Keele, L., and Teppeti, Y. (2010). Identification, Inference and Sensitivity Analysis for Causal Mediation. *Stat. Sci.* 25, 51–71. doi:10.1214/10-STS321

Imai, K., Keele, L., and Tingley, D. (2010). A General Approach to Causal Mediation Analysis. *Psychol. Methods* 15, 309–354. doi:10.1037/a0020761

Imai, K., and Yamamoto, T. (2013). Identification and Sensitivity Analysis for Multiple Causal Mechanisms: Revisiting Evidence from Framing Experiments. *Polit. Anal.* 21, 141–171. doi:10.1093/pan/mps040

Inohshita, M., Numata, S., Tajima, A., Kinoshita, M., Umehara, H., Yamamori, H., et al. (2015). Sex Differences of Leukocytes DNA Methylation Adjusted for Estimated Cellular Proportions. *Biol. Sex Differences* 6. doi:10.1186/s13293-015-0029-7

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

PX and TW conceived the idea behind the article and designed the study and prepared the draft of the manuscript. PS conducted the literature review and the revision of the manuscript. TW advised on critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

FUNDING

This work was supported by National Natural Science Foundation of Shandong Province (ZR 2019PH041).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.831885/full#supplementary-material
Jaffe, A. E., and Irizarry, R. A. (2014). Accounting for Cellular Heterogeneity Is Critical in Epigenome-wide Association Studies. Genome Biol. 15, R31. doi:10.1186/gb-2014-15-2-r31

Jenkins, T. G., James, E. R., Alonso, D. F., Hoodal, J. R., Murphy, P. J., Hotaling, J. M., et al. (2017). Cigarette Smoking Significantly Alters Sperm DNA Methylation Patterns. Andrology 5, 1089–1099. doi:10.1111/andr.12416

Joehanes, R., Just, A. C., Marioni, R. E., Pilling, L. C., Reynolds, L. M., Mandaviya, P. R., et al. (2016). Epigenetic Signatures of Cigarette Smoking. Circ. Cardiovasc. Genet. 9, 436–447. doi:10.1161/CIRCCGENETICS.116.001506

Kalla, R. A. A. N. J. (2021). Analysis of systemic epigenetic alterations in inflammatory bowel disease: de ning geographical, genetic, and immune-in amputation in utero on the circulating methylome. doi:10.21203/rs.3-r537439/v1

Kang, E. Y., Ye, C., Shipitser, L., and Eskin, E. (2010). Detecting the Presence and Absence of Causal Relationships between Expression of Yeast Genes with Very Few Samples. J. Comput. Biol. 17, 533–546. doi:10.1089/cmb.2009.0076

Karatzas, P. S., Gazouli, M., Safioleas, M., and Mantzaris, G. J. (2014). DNA Methylation Changes in Inflammatory Bowel Disease. Ann. Gastroenterol. 27, 125–132.

Khasawneh, M., Spence, A. D., Addley, J., and Allen, P. B. (2017). The Role of Smoking and Alcohol Behaviour in the Management of Inflammatory Bowel Disease. Best Pract. Res. Clin. Gastroenterol. 31, 533–539. doi:10.1016/j.bpg.2017.10.004

Kular, L., Liu, Y., Ruhrmann, S., Zheleznyakova, G., Marabita, F., Gomez-Cabrero, D., et al. (2018). DNA Methylation as a Mediator of HLA-Drb1*15:01 and a Protective Variant in Multiple Sclerosis. Nat. Commun. 9, 2397. doi:10.1038/s41467-018-04732-5

Lee, K. W. K., and Pausova, Z. (2013). Cigarette Smoking and DNA Methylation. Front. Genet. 4, 132. doi:10.3389/fgene.2013.00132

Lin, Z., Hegarty, J. P., Cappel, J. A., Yu, W., Chen, X., Faber, P., et al. (2011). Identification of Disease-Associated DNA Methylation in Intestinal Tissues from Patients with Inflammatory Bowel Disease. Clin. Genet. 80, 59–67. doi:10.1111/j.1399-0004.2010.01546.x

Liu, Y., Aryee, M. J., Padyukov, L., Fallin, M. D., Hesselberg, E., Runnarson, A., et al. (2013). Epigenome-wide Association Data Implicate DNA Methylation as an Intermediary of Genetic Risk in Rheumatoid Arthritis. Nat. Biotechnol. 31, 142–147. doi:10.1038/nbt.2487

Maltepe, P., Palma, L., Sfara, C., de Rocco, P., Latiano, A., Palmieri, O., et al. (2012). Glucocorticoid Resistance in Crohn’s Disease and Ulcerative Colitis: an Association Study Investigating GR and FKBP5 Gene Polymorphisms. Pharmacogenomics J. 12, 432–438. doi:10.1007/s13298-011-0026-6

McDermott, E., Ryan, E. J., Tosetto, M., Gibson, D., Burrage, J., Keegan, D., et al. (2015). DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. J. Crohn’s Colitis 10, 77–86. doi:10.1093/ccc/jv176

Nicolaidis, K., Vasudevan, A., Long, T., and van Langenberg, D. (2021). The Impact of Tobacco Smoking on Treatment Choice and Efficacy in Inflammatory Bowel Disease. Intestinal Res. 19, 158–170. doi:10.5217/ir.2020.00008

Reißig, S., Tang, Y., Nikolaev, A., Gerlach, K., Wolf, C., Davari, K., et al. (2017). Elevated Levels of Bcl-3 Inhibits Treg Development and Function Resulting in Spontaneous Colitis. Nat. Commun. 8, 15069. doi:10.1038/s41590-015069

Relton, C. L., and Davey Smith, G. (2012). Two-step Epigenetic Mendelian Randomization: a Strategy for Establishing the Causal Role of Epigenetic Processes in Pathways to Disease. Int. J. Epidemiol. 41, 161–176. doi:10.1093/ije/dys233

Severs, M., van Erp, S. J. H., van der Valk, M. E., Mengen, M. J. J., Fiddler, H. H., van der Have, M., et al. (2016). Smoking Is Associated with Extra-intestinal Manifestations in Inflammatory Bowel Disease. J. Crohn’s Colitis 10, 453–461. doi:10.1093/ccc/jcv238

Sharp, G. C., Arathimos, R., Reese, S. E., Page, C. M., Felix, J., Küppers, L. K., et al. (2018). Maternal Alcohol Consumption and Offspring DNA Methylation: Findings from Six General Population-Based Birth Cohorts. Epigenetics 10, 27–42. doi:10.2217/epi-2017-0095

Shu, C., Justice, A. C., Zhang, X., Wang, Z., Hancock, D. B., Johnson, E. O., et al. (2020). DNA Methylation Mediates the Effect of Cocaine Use on HIV Severity. Clin. Epigenetics 12. doi:10.1186/s13148-020-00934-1